REPARE THERAPEUTICS INC (RPTX) Stock News
NASDAQ:RPTX - Nasdaq - US7602731025 - Common Stock - Currency: USD
RPTX Latest News, Press Relases and Analysis
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions
Neue Möglichkeiten der Krebsbehandlung durch hochmoderne Immuntherapien
/PRNewswire/ -- USA News Group Nachrichtenkommentar – Die jüngsten Fortschritte in der Krebsbehandlung demonstrieren weiterhin das transformative Potenzial...
Les immunothérapies de pointe redéfinissent les options de traitement du cancer
/PRNewswire/ -- USA News Group News Commentary - Les récentes avancées dans le traitement du cancer continuent de souligner le potentiel transformateur des...
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options
/PRNewswire/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative...
RPTX Stock Earnings: Repare Therapeutics Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Repare Therapeutics (NASDAQ:RPTX) just reported results for the first quarter o...
Why Is Repare Therapeutics Stock Trading Lower On Friday?
On Thursday, Repare Therapeutics Inc (NASDAQ:RPTX) revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers. As of the data cut-off date of November 14, 51 evaluable patients were enrolled in the gynecologic cancer expansion cohort of the MYTHIC trial. Across all tumor types treated at the optimized RP2D (n=67),
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib
Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results
Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're diving into the biggest pre-market stock movers for Wednesday will a look at all of the latest news happening this morning.